The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors by Massi, D. et al.
RESEARCH ARTICLE Open Access
The density and spatial tissue distribution
of CD8+ and CD163+ immune cells predict
response and outcome in melanoma
patients receiving MAPK inhibitors
Daniela Massi1, Eliana Rulli2, Mara Cossa3,4, Barbara Valeri4, Monica Rodolfo3, Barbara Merelli5, Francesco De Logu6,
Romina Nassini6, Michele Del Vecchio7, Lorenza Di Guardo7, Roberta De Penni8, Michele Guida9,
Vanna Chiarion Sileni10, Anna Maria Di Giacomo11, Marco Tucci12, Marcella Occelli13, Francesca Portelli1,
Viviana Vallacchi3, Francesca Consoli14, Pietro Quaglino15, Paola Queirolo16, Gianna Baroni1,
Fabrizio Carnevale-Schianca17, Laura Cattaneo18, Alessandro Minisini19, Giuseppe Palmieri20, Licia Rivoltini3*,
Mario Mandalà5 and on behalf of the Italian Melanoma Intergroup
Abstract
Background: Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons
still needing to be elucidated. As the patient immune activity contributes to treatment clinical benefit, the pre-
existing level of immunity at tumor site may provide biomarkers of disease outcome to therapy. Here we
investigated whether assessing the density and spatial tissue distribution of key immune cells in the tumor
microenvironment could identify patients predisposed to respond to MAPK inhibitors.
Methods: Pretreatment tumor biopsies from a total of 213 patients (158 for the training set and 55 for the
validation set) treated with BRAF or BRAF/MEK inhibitors within the Italian Melanoma Intergroup were stained with
selected immune markers (CD8, CD163, β-catenin, PD-L1, PD-L2). Results, obtained by blinded immunohistochemical
scoring and digital image analysis, were correlated with clinical response and outcome by multivariate logistic models
on response to treatment and clinical outcome, adjusted for American Joint Committee on Cancer stage, performance
status, lactate dehydrogenase and treatment received.
Results: Patients with high intratumoral, but not peritumoral, CD8+ T cells and concomitantly low CD163+ myeloid
cells displayed higher probability of response (OR 9.91, 95% CI 2.23–44.0, p = 0.003) and longer overall survival (HR 0.34,
95% CI 0.16–0.72, p = 0.005) compared to those with intratumoral low CD8+ T cells and high CD163+ myeloid cells. The
latter phenotype was instead associated with a shorter progression free survival (p = 0.010). In contrast, PD-L1 and PD-
L2 did not correlate with clinical outcome while tumor β-catenin overexpression showed association with lower
probability of response (OR 0.48, 95% CI 0.21–1.06, p = 0.068).
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: licia.rivoltini@istitutotumori.mi.it
3Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
Full list of author information is available at the end of the article
Massi et al. Journal for ImmunoTherapy of Cancer           (2019) 7:308 
https://doi.org/10.1186/s40425-019-0797-4
(Continued from previous page)
Conclusions: Analysis of the spatially constrained distribution of CD8+ and CD163+ cells, representative of the opposite
circuits of antitumor vs protumor immunity, respectively, may assist in identifying melanoma patients with improved
response and better outcome upon treatment with MAPK inhibitors. These data underline the role of endogenous
immune microenvironment in predisposing metastatic melanoma patients to benefit from therapies targeting driver-
oncogenic pathways.
Keywords: Myeloid cells, T lymphocytes, Microenvironment, Melanoma prognosis
Introduction
Approximately 40–50% of metastatic melanoma patients
(MPs) harbor point mutations in BRAF, over 95% of which
are at V600 in BRAF exon 15 [1]. The discovery of this mu-
tation provided the genetic basis for the development of
BRAF inhibitors (BRAFi) for the treatment of melanoma.
Clinical efficacy of this class of drugs was initially demon-
strated by their use in mono-therapy in patients with BRAF
V600-mutant melanoma. In two prospective randomized
clinical trials BRAFi showed a better response rate, pro-
gression free survival (PFS) and overall survival (OS) than
chemotherapy [2, 3]. However, responses were temporally
limited, mainly because of acquired resistance. Improve-
ment of efficacy and tolerability was attained with dual
MAPK pathway inhibition by adding a MEK inhibitor
(MEKi) to a BRAFi as reported in phase 3 randomized
studies [4–6]. Therefore, BRAFi/MEKi combination has
been recommended as a standard therapy for advanced
BRAF V600-mutated melanoma, being associated with a
median PFS and OS of 12months and 24–36months, re-
spectively [4–6]. Albeit the problem of overcoming primary
and acquired resistance still needs to be faced for thera-
peutic amelioration, about 30–35% of patients are alive at
5 years indicating the onset of long-term tumor control [7].
The identification of biomarkers that predict durable bene-
fit in patients with BRAFV600-mutated melanoma would
provide essential tools for better treatment personalization.
Beside the effect on the biological target and pathway,
there is strong evidence that the therapeutic efficacy of
BRAFi and MEKi relies on additional factors involved in
tumor-host interactions and preclinical data show that onco-
genic BRAF contributes to immune evasion, as targeting this
mutation may increase melanoma immunogenicity [8].
Several genomic mechanisms of intrinsic or acquired
tumor resistance to MAPKi therapies have been reported,
including BRAFV600 amplification and single nucleotide
variants in NRAS, KRAS, MEK1/2, PTEN, CDKN2A and
DUSP4 [9]. A study comparing the genomic features of
complete responders (CR) versus fast progressors (PD) in
patients treated with BRAFi/MEKi showed higher rates of
MITF amplification and TP53 mutation in PD, whereas
NF1 deletion and deleterious mutations were more com-
mon in CR [10]. Nevertheless, gene signatures of CD8 T ef-
fector cells, cytolytic T-cells, antigen presentation and NK
cells were significantly enriched in CR tumors [10]. Indeed,
several evidences support a key role of tumor immunity in
the therapeutic efficacy of MAPKi. LEF1 down-expression
and β-catenin induction, which reduce T cells and CD103+
dendritic cells tumor infiltrate via inhibition of CCL4 secre-
tion [11], have been reported to promote acquired resist-
ance to BRAFi and MEKi [12]. A rapid accrual of activated
CD8+ T cells in tumor microenvironment is instead trig-
gered by BRAFi administration at early time points [13], in
association with clinical benefit [14]. Preclinical studies
linked this effect to the upregulation of HLA molecule ex-
pression in tumor cells, favoring increased antigen presen-
tation and activation of antitumor T cells, together with the
downregulation of certain immunosuppressive factors such
as PD-L1, IL1, IL8, NT5E, and VEGFA [15]. On the other
hand, non responding patients are featured by the accrual in
the tumor site and peripheral blood of myeloid immunosup-
pressive cell elements and macrophages [16], again pointing
to immunity as a key player to MAPKi therapeutic activity.
Based on these data, we designed a study aimed at identi-
fying essential tissue immune biomarkers able to capture
the immune contexture of tumor microenvironment that
could potentiate or contrast the clinical efficacy of MAPKi.
Materials and methods
Patient characteristics
The cohort of the training set (n = 158) was identified by
inspecting the electronic databases of all metastatic MPs
treated at Italian Melanoma Intergroup (IMI) centers
from June 2011 to February 2017. We retrieved data
concerning clinical outcome and MAPKi treatment from
patients enrolled in compassionate, expanded access use
protocols or therapeutic use of BRAFi with or without
MEKi since 2011. The local Ethics Committees approved
the study protocol. The study was conducted in compli-
ance with the World Medical Association Declaration of
Helsinki. Patients enrolled in the study were treated with
vemurafenib or vemurafenib and cobimetinib within the
therapeutic and expanded access use according to clin-
ical practice. For patients included in the vemurafenib
compassionate program use, the inclusion criteria were
an Eastern Cooperative Oncology Group performance
status (ECOG-PS) 0–2, as well as normal hepatic (serum
bilirubin < 1.5 mg/dl), renal (serum creatinine < 1.5 mg/
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dl) and bone marrow (leucocyte count > 4000/1 l, plate-
let count > 100,000/1 l) functions. For the other patients,
exclusion criteria were a rapid deteriorating medical con-
dition, with severe liver or renal failure, QTc > 500 mS
and ECOG-PS 4. Information on age, gender, histopath-
ology, and surgical and medical treatment were retrieved
for each patient, as well as data on tumor objective
response rate (ORR), PFS and OS. Data on treatment and
survival were collected prospectively. Medical records
and/or review of pathology material confirmed accuracy
in histopathological classification. Tumor stage was
assessed according to the American Joint Committee on
Cancer (AJCC) TNM (Tumor, Node, Metastasis) staging
system classification (VII edition). Clinical response to
BRAFi/MEKi was assessed by RECIST v1.1 criteria [17].
Patients of the validation set (n = 55) were instead
treated at the Istituto Nazionale dei Tumori of Milan, with
BRAFi according to the MO25515 trial (multicenter phase
II study on first−/second-line Vemurafenib; ClinicalTrials.
gov, NCT01307397) [18] (n = 35) or BRAFi/MEKi by clin-
ical practice (n = 20). Similarly to the training cohort
ECOG-PS was 0–2, normal hepatic (serum bilirubin < 1.5
mg/dl), renal (serum creatinine < 1.5 mg/dl) and bone
marrow (leucocyte count > 4000/1 l, platelet count > 100,
000/1 l) functions was required to receive targeted ther-
apy. Information on demographics was retrieved for each
patient, as well as data on PFS and OS. Data on treatment
and survival were collected prospectively.
Tissue samples
Formalin fixed paraffin-embedded (FFPE) tissue sections,
4 μm in thickness, were stained with hematoxylin and eosin
and centrally reviewed to confirm the histopathological
diagnosis and to assess pathology tissue quality control.
Immunohistochemistry
Representative 4-μm thick FFPE tissue sections of pre-
treatment melanoma samples were selected for immuno-
histochemical analysis. Sections were incubated with the
following primary antibodies: CD8 (rabbit monoclonal
CONFIRM, clone SP57 ready to use; Ventana Medical Sys-
tems, Tucson, AZ), CD163 (mouse monoclonal, clone
10D6, dilution 1:100, Novocastra Laboratories Ltd., New-
castle, UK), β-catenin (mouse monoclonal, clone 14 ready
to use, Ventana Medical Systems, Tucson, AZ), PD-L1
(rabbit monoclonal, clone E1L3N, dilution 1:50, Cell Signal-
ing, Danvers, USA) and PD-L2 (rabbit monoclonal, clone
D7U8C, dilution 1:50, Cell Signaling, Danvers, USA) on a
Ventana BenchMark ULTRA immunostainer (Ventana
Medical Systems, Tucson, AZ). The staining procedure in-
cluded pretreatment with cell conditioner 1 followed by in-
cubation with the different antibodies. For all antibodies,
the signal was developed with the Universal Red Detection
Kit (Ventana Medical Systems, Tucson, AZ). Sections were
then counterstained with hematoxylin. Tissue sections of
tonsil were used as positive control. As negative controls,
mouse IgG1 isotype control was used for β-catenin and
CD163 while rabbit IgG isotype control was used for CD8,
PD-L1 and PD-L2, respectively. The control sections were
treated in parallel with the samples.
Immunohistochemical scoring was performed in a
blinded fashion by experienced melanoma pathologists
(DM, MC, BV). Stained sections were initially assessed
at low magnification to select the areas with highest
density of positive immune cells at peritumoral and
intratumoral location. Assessment of CD8+ T lympho-
cytes and CD163+ macrophages score density was com-
pared with evaluation obtained by image analysis.
Evaluation of tumoral β-catenin and PD-L1 was per-
formed as previously described [19, 20]. PD-L2 expres-
sion was evaluated on tumor cells. Assessment of the
training set was centralized in the University of Florence,
while the validation set was evaluated at the Istituto
Nazionale dei Tumori of Milan, according to shared
standard operating procedures.
Digital image acquisition and analysis
Tissue sections stained with CD8 and CD163 antibodies
were digitally scanned at an absolute magnification of
X200 using D-Sight platform (A. Menarini Diagnostic,
Florence, Italy). An algorithm was designed based on pat-
tern recognition that quantified CD8+ and CD163+ cells
within two tumor compartments: the invasive tumor mar-
gin (stromal-tumor edge) and inside the tumor paren-
chyma (tumor center). Image analysis based on RGB (red,
green, blue) spectra was used to detect all cells by counter-
staining with hematoxylin (blue) and fast red. The number
of fast red CD8+ and CD163+ cells was calculated in five
different high-power magnification fields of 10− 3 mm2.
The algorithm calculated the density of CD8+ and
CD163+ cells/mm2. The total number of CD8+ and
CD163+cells was then calculated as the mean of each
high-power magnification field. CD8 and CD163 expres-
sion was determined using two read-outs that were inde-
pendent of each other to account for tumor heterogeneity.
The immune cell density (CD8+ and CD163+ cells) at
the peritumoral area was further explored in order to
generate a cell density histogram. The peritumoral com-
partment was defined as the region centered on the
border separating the host tissue from the malignant
nests, with an extent of 500 μm. To analyze further the
spatial distribution of CD8+ and CD163+ cells in the
peritumoral area, an algorithm was designed to create
thick bands (1 mm2) 20 μm internal and external to the
tumor margin. Then, the distribution of the CD8+ and
CD163+ cells related to the tumor margin was identified
in consecutive 20 μm steps (distance classes) within
100 μm (Fig. 1).
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Statistical analysis
PFS was defined as the time from the date of start treat-
ment to the date of progression or death from any cause
whichever comes first. Patients who did not progress or
die at the date of analysis were censored at their last
disease assessment date. OS was defined as the time from
the date of start treatment to the date of death from any
cause. Overall response rate (ORR) was defined as the
proportion of patients with a complete or partial response
to treatment. Survival curves were estimated with the
Kaplan-Meier method. PFS and OS were analyzed by
means of Cox regression model and results were
expressed as hazard ratios (HR) with their 95% confidence
intervals (95% CI). ORR was analyzed by means of logistic
regression models and expressed as odds ratios (OR) with
their 95% CI. All multivariate models included as covari-
ates immunohistochemical variables, AJCC stage, per-
formance status, lactate dehydrogenase (LDH) and the
treatment received (BRAFi+MEKi vs BRAFi alone). OS
multivariable models included also the subsequent treat-
ment (immunotherapy vs no immunotherapy).
PD-L1 and PD-L2 were tested as a continuous or as a di-
chotomous variable using 5% as cut-off. Score density of
CD8+ T cells and CD163+ macrophages in intratumoral
and peritumoral location was assessed as follows: 0, absent;
1+, mild (< 10%); 2+, moderate (10–50%); 3+, marked (50–
100%) and their density was evaluated as dichotomous
variable as high (2+, 3+) versus low (0, 1+). β-catenin was
tested as a continuous or as a dichotomous variable using
the median value as cut-off. CD8+ T cells and CD163+
macrophages were also analyzed in combination, categoriz-
ing patients in three groups: group 1, high CD8+ T cells
and low CD163+ macrophages; group 2, high CD8+ T cells
and high CD163+ macrophages/low CD8+ T cells and low
CD163+ macrophages; group 3, low CD8+ T cells and high
CD163+ macrophages. CD8+ T cells and immunohisto-
chemical PD-L1 overexpression were combined in three
groups as follow: group 1, PD-L1 ≥ 5% and low CD8+ T
cells; group 2, PD-L1 ≥ 5% and high CD8+ T cells/PD-L1 <
5% and low CD8+ T cells; group 3, PD-L1 < 5% and high
CD8+ T cells. Combining β-catenin expression and CD8+ T
cells, patients were categorized in three groups: group 1,
low CD8+ T cells and β-catenin overexpressed; group 2,
high CD8+ T cells and β-catenin overexpressed/low CD8+
T cells and β-catenin not overexpressed; group 3, high
CD8+ T cells and β-catenin not overexpressed.
Chi square test was used to assess associations between
PD-L1, PD-L2, β-catenin, CD8+ and CD163+ status and
Fig. 1 Representative metastatic melanoma tissue with analysis mark-up (a). Panel A illustrates a CD8 stain; red dashed line is the invasive tumor
margin. CD8+ and CD163+ cells are counted within the invasive margin, 100 μm inside and 100 μm outside the tumor as identified with green
and orange lines spaced 20 μm. b, c CD8+ and CD163+ cells’ density is binned according to the distance from the margin and a 20 μm bin
histogram is generated. The middle of the histogram if the tumor boundary (red dashed line), to the left is inside tumor (green bars) and to the
right is outside tumor (orange bars)
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other clinical and pathological features. The Kruskal-
Wallis test was used to analyze the association between
the cell count and the density score in CD8+ T cells and
CD163+ macrophages.
To test the robustness of the results, an independent
series of metastatic MPs was analyzed separately as valid-
ation cohort. The validation cohort included metastatic
MPs who received BRAFi or BRAFi plus MEKi at the Isti-
tuto Nazionale dei Tumori of Milan; their inclusion and ex-
clusion criteria were the same as those for the training set.
All tests were two sided and the statistical significance
was set at < 0.05 for each analysis. Statistical analyses were
carried out using SAS version 9.4 (SAS Institute, Cary,
NC) and R language environment for statistical computing
(open source, www.r-project.org version 3.4.3).
Results
Patients and treatments
Demographic and clinical characteristics of the training
set included are summarized in Additional file 1: Table
S1. 158 patients were enrolled in the training set; 60 %
of patients were male, and the median age at diagnosis
of metastatic disease was 59 years (Q1-Q3: 47.7–70.7).
All patients had metastatic disease, 60% with M1c dis-
ease (95 patients). One hundred and thirty-six patients
(86%) and 22 patients (14%) received MAPKi as 1st- or
2nd-line therapy, respectively. Ninety-four patients
(60%) received BRAFi as a monotherapy, while 64 pa-
tients (40%) received BRAFi+MEKi. The most frequent
subsequent lines of treatment were immunotherapy and
chemotherapy in 25 and 17% of patients, respectively.
Approximately 56% of patients were not treated with
further treatments because of rapid progressive disease.
Patients of the validation set were comparable to the
training set cohort for demographics and clinical param-
eters. Thirty patients (55%) were male; all patients had
metastatic disease and 55% with M1c disease (30
patients). Thirty-five patients (64%) received BRAFi as a
monotherapy, while 20 patients (36%) received BRAFi+-
MEKi. Twelve patients (22%) received immunotherapy
as a subsequent line of therapy.
Immunohistochemical β-catenin, PD-L1, PD-L2, CD8 and
CD163 expression in melanoma samples
A panel of representative immune markers was tested by
immunohistochemistry on melanoma biopsies from the
training set, including PD-L1 and PD-L2 (included as sur-
rogates of inflammed tumors and tumor immune escape),
β-catenin (chosen as tumor pathway driving immune-
suppressed microenvironment), CD8 (as marker of antitu-
mor effector T cells) and CD163 (recapitulating tumor as-
sociated myeloid cells including macrophages). Immune
markers expression was evaluated in the last available
metastatic sample before starting MAPKi therapy in 122
patients (Fig. 2, Additional file 2: Fig. S1 and S2). In the
remaining cases, biomarkers were evaluated in the pri-
mary melanoma samples due to unavailability of meta-
static tissue. The median interval between metastatic
biopsies and treatment starting was 3months (range 1–6
months). PD-L1 expression on the tumor cell membrane
was negative in 82 patients (57%), positive in 63 patients
(43%) and technically not evaluable (NE) in 15 patients,
while PD-L2 was negative in 126 patients (89%), positive
in 15 (11%) patients and NE in 18 patients. The median
expression of β-catenin was 60% (interquartile range
(IQR): 20–80, NE, in 9 patients), 0 (IQR: 0–0, N NE A:
11 patients) and 10 (IQR: 0–80, NE: 9 patients) for
membranous, nuclear and cytoplasmic expression, re-
spectively. These values were used as cut-offs to analyze
β-catenin as dichotomous variable.
The expression of PD-L1 was associated with high
intratumoral CD163+ macrophages (p = 0.008) and high
peritumoral CD163+ cells (p = 0.032), conversely PD-L1
expression was not associated neither with intratumoral
nor with peritumoral CD8+ T-cell melanomas (Add-
itional file 1: Table S2).
Density and spatial distribution of the above men-
tioned immune markers were then divided in discrete
categories, and their prevalence is reported in Additional
file 1: Table S3 and Additional file 2: Figure S3.
The impact of tissue biomarkers on ORR
Treatment response was available for 156 patients and
included 26 (16.7%) complete responses; 73 (46.8%) par-
tial responses; 25 (16.0%) stable disease and 32 (20.5%)
progressive disease. The distribution of responder pa-
tients according to intra and peritumoral CD8+ T-cell
and CD163+ macrophages density is reported in Fig. 3.
Results of multivariate logistic models on response to
treatment, adjusted for AJCC stage, performance status,
LDH and treatment received (BRAFi+MEKi vs BRAFi),
are reported in Additional file 1: Table S4. Metastatic MPs
with high intratumoral CD8+ T-cell count (OR 2.15 95%
CI 0.93–4.98, p = 0.074) had a higher probability of re-
sponse to treatment, while those with membranous β-
catenin overexpression > 60% (OR 0.48, 95% CI 0.21–1.06,
p = 0.068) showed a lower probability of response. Meta-
static MPs with high intratumoral CD163+ count (OR
0.28, 95% CI 0.12–0.65, p = 0.003) had a statistically sig-
nificant lower probability of response, while the same pro-
file (high CD163+ macrophages) in the peritumoral space
did not reach any statistical difference (p = 0.136) (Add-
itional file 1: Table S4). The rate of CR was 24% vs 4%
among patients with high CD8+/low CD163+ immuno-
phenotype, respectively (p = 0.04).
Furthermore, a statistically significant higher probabil-
ity of response was observed in patients with β-catenin
negative and high intratumoral CD8+ T-cell count
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compared to those with β-catenin overexpression and
low intratumoral CD8+ melanomas (Additional file 1:
Table S4).
Interestingly, when patients were analyzed according
to the combined evaluation of the intratumoral and peri-
tumoral density of CD8+ and CD163+ cells, a higher
probability of response was observed in patients with
high intratumoral, but not peritumoral, CD8+ T cells
and low CD163+ macrophages compared to those with
low intratumoral CD8+ T cells and high intratumoral
CD163+ macrophages (OR 9.91, 95% CI 2.23–44.0, p =
0.003) (Additional file 1: Table S4).
The impact of tissue biomarkers on PFS and OS
At a median follow-up of 34months, 121 (78.1%) patients
had progressed and 109 (69.0%) had died. Overall, 126
(79.7%) patients progressed or died. The median PFS and
OS were 8.3 (IQR: 4.6–19.2) and 13.7 (IQR: 6.1–38.6)
months, respectively.
Results of multivariate analysis, both for PFS and OS are
reported in Fig. 4 and Additional file 1: Table S5. At
multivariate assessment, a shorter PFS was observed in pa-
tients with intratumoral, but not peritumoral, low CD8+ T
cells and high CD163+ macrophages (p = 0.010) (Fig. 4,
Additional file 1: Table S5). At multivariate analysis, after
Fig. 2 Representative metastatic melanoma tissues showing intratumoral low CD8+/ high CD163+ expression (a, b); intratumoral high CD8+/low
CD163+ expression (c, d). (original magnification 10x, scale bar 100 μm, insert 40x, scale bar 20 μm); peritumoral low CD8+/high CD163+
expression (e, f); peritumoral high CD8+/low CD163+ expression (g, h). (original magnification 10x, scale bar 100 μm, insert 40x, scale bar 20 μm)
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adjusting for stage, LDH, PS, treatment received (BRAFi+-
MEKi vs BRAFi), subsequent immunotherapy (yes/no),
metastatic MPs with high intratumoral, but not peritu-
moral, CD8+ T cells density showed a barely detectable
statistically significant difference in terms of OS (HR 0.65,
95% CI 0.41–1.04, p = 0.072) (Fig. 4). Notably, patients
with high intratumoral, but not peritumoral, CD8+ T cells
and low intratumoral CD163+ macrophages (HR 0.34, 95%
CI 0.16–0.72, p = 0.005) had a longer OS compared to
those with intratumoral low CD8+ T cells and high
CD163+ macrophages. Figure 5 and Fig. 6 show Kaplan-
Meier curves for OS according to CD8+ T cell and CD163+
macrophages alone or in combination, respectively.
Validation cohort: impact of tissue biomarkers on PFS
and OS
Patients of the validation case set (n = 55) were
enrolled and evaluated independently at the Istituto
Nazionale dei Tumori of Milan. Patient demographic
and clinical characteristics are summarized in Add-
itional file 1: Table S6.
At a median follow-up of 41.5months, 45 (81.8%) pa-
tients had progressed and 12 (21.8%) had died. Overall, 45
(78.2%) patients progressed or died. The median PFS was
9.3 (IQR: 5.8–48.0), while the median OS was not reached.
Results of multivariate analysis for PFS and OS are re-
ported in Fig. 7. At multivariate assessment, after adjust-
ing for stage, treatment received (BRAFi+MEKi vs
BRAFi), a shorter PFS was observed in patients with
intratumoral low CD8+ T cells and high CD163+ macro-
phages (p < 0.001 and p = 0.002 for CD8+ and CD163+,
respectively) (Fig. 7). Regarding OS, at multivariate ana-
lysis, after adjusting for stage, treatment received (BRA-
Fi+MEKi vs BRAFi) and subsequent immunotherapy
(yes vs no), metastatic MPs with high intratumoral, but
not peritumoral, CD8+ T cells density showed a statisti-
cally significant better prognosis (HR 0.14, 95% CI 0.03–
0.69, p = 0.016 for intratumoral and HR 0.26, 95% CI
0.06–1.08, p = 0.064 for peritumoral CD8+ T cells) (Fig.
7). Notably, patients with high intratumoral CD8+ T
cells and low intratumoral CD163+ macrophages (HR
0.04, 95% CI 0.00–0.50, p = 0.013) had a longer OS
Fig. 3 Response to treatment according to intratumoral and peritumoral density CD8+ T cells and CD163+ macrophages. Low: score = 0, 1+; High:
score = 2+,3+; non responder: patients who have experienced a stable or progressive disease as best response to therapy; responder: patients
who have experienced a complete or partial response as best response to therapy
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compared to those with intratumoral low CD8+ T cells
and high CD163+ macrophages (Fig. 7).
Discussion
Increasing evidence indicates that response and long-term
outcome to treatment with MAPKi in melanoma patients
is influenced by clinical prognostic parameters related
mostly to tumor burden and aggressiveness features.
While the initial clinical response to MAPKi primarily re-
lies on the loss of kinase activity of ERK, subsequent adap-
tive events appear to be mediated by the intervening
action of immune cells. Accordingly, strategies to improve
long-term responses to MAPKi necessarily require a bet-
ter understanding of the diverse cellular patterns of the
complex tissue microenvironment (TME). In this timely
context of clinical and translational research, the three
most striking findings of this study are: 1) metastatic MPs
with absent/low infiltration of CD8+ T cells and a high
density of CD163+ macrophages at intratumoral, but not
peritumoral location, had a statistically significant shorter
OS compared to those with high density CD8+ T cells and
absent/low density of CD163+ macrophages. 2) metastatic
MPs with absent/low intratumoral CD8+ T cells and high
intratumoral CD163+ macrophages showed a nearly statis-
tically significant shorter PFS compared to those with the
opposite profile, while the same profile (low CD8+ T cells/
high CD163+ macrophages) in the peritumoral space did
not exhibit any tendency; 3) the response rate of patients
with high intratumor CD163+ macrophages was lower
than those with absent or low CD163+ intratumor infiltra-
tion, while the response rate was not affected by changes
in the peritumoral CD163+ macrophages. Thus, both the
density and distribution of CD163+ macrophages seem to
determine the biological and clinical events associated
with ORR. One of the major issues in exploiting MAPKi
for metastatic melanoma patients lies in the interpatient
degree and duration of response: some patients progress
upon treatment, while others achieve complete response,
and the remainder is somewhere in between. Hence, there
is a clinical need to identify biomarkers that can allow ac-
curate identification of the best treatment approach in the
individual patient with BRAF-mutated melanoma. Identi-
fying biomarkers correlated with a higher probability of
response and a longer PFS could be clinically and transla-
tionally relevant for two main reasons: i) in symptomatic
patients or in those who are candidate to a neoadjuvant
approach the probability and the degree of response could
be important to identify patients who can draw a remark-
able and sustained response to treatment, which in turns
correlates with a good prognosis; ii) several studies
showed that the high and prolonged response correlates
with better outcome. The rate of CR is indeed a surrogate
biomarker strongly correlated with long term outcome in
several prospective studies investigating the efficacy of tar-
geted therapy in melanoma [21, 22].
For this reason we assessed the rate of patients who
achieved a complete response to targeted therapy according
to the investigated biomarkers in the TME. In our series,
the rate of CR was significantly increased in MPs with high
CD8+/low CD163+ versus those with low CD8+/high
CD163+ immunophenotype. Our study, by identifying sim-
ple and reliable biomarkers correlated with response and
Fig. 4 Forest plot on progression free survival and overall survival -Multivariable Cox regression model – Impact of tissue biomarkers on
progression free survival and overall survival. Legend: #Adjusted for Stage, LDH, PS, treatment (BRAFi+MEKi vs BRAFi); ## Adjusted for Stage, LDH,
PS, treatment (BRAFi+MEKi vs BRAFi), subsequent Immunotherapy (yes/no); i: intratumoral; p: peritumoral; CD8+/ CD163+ low: score 0,1+, high:
score 2+,3 +
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longer PFS, could be translationally and clinically rele-
vant. Reproducible biomarker measurements are essen-
tial, particularly for long-term projects with valuable
patient samples.
Our results showed an uneven spatial distribution of im-
mune cells in the intra- and peritumoral space, and
allowed to combine these cellular biomarkers in biosigna-
tures with opposing roles, favoring or disfavoring response
and better prognosis of metastatic MPs treated with
BRAFi/MEKi, [13, 14, 23]. We suggest that none of the
biomarkers taken individually is able to predict the long-
term outcome of patients receiving MAPKi. Only the com-
bination of multiple markers is therefore able to reflect the
complexity of the TME and to predict the outcome of pa-
tients. Furthermore, our findings support the hypothesis
that a more hostile TME at baseline is associated with a
worse ORR and outcome in BRAFV600-mutated metastatic
MPs receiving MAPKi. However, in our cohort, tumor
overexpression of PD-L1 or β-catenin in association with
intratumoral or peritumoral CD8+ T lymphocytes or
CD163+ was not an independent prognostic factor at
multivariate analysis. Consistently with our previous study,
we found that a statistically significant higher probability of
response was observed in metastatic MPs with β-catenin
negative and high intratumoral CD8+ T-cell count com-
pared to those with β-catenin overexpression and low
intratumoral CD8+ melanomas [19]. Nevertheless, we pre-
viously reported a better OS in metastatic MPs with high
density of CD8+ T lymphocytes and no overexpression of
β-catenin, than those with no CD8+ T lymphocytes and
overexpression of β-catenin [19]. Incorporating the evalu-
ation of both CD8+ T cells and CD163+ macrophages at-
tenuates the predictive power of β-catenin in identifying
MAPKi-treated metastatic MPs with better outcome. The
key role of CD8+ T cells recruited into the tumor compart-
ment is underlined by the adoptive T cell transfer proto-
cols developed in melanoma that have consistently yielded
high and durable clinical response in selected pa-
tients [24]. However, our data further support the
implication of CD163+ cells in dominant inhibitory
pathways in melanoma, implying that the presence
of protumor and immunosuppressive myeloid cells as
Fig. 5 Kaplan-Meier curves for overall survival according to intratumoral CD8+ T cells (a), peritumoral CD8+ T cells (b), intratumoral
CD163+macrophages (c), peritumoral CD163+ macrophages (d). Low: score = 0, 1+; High: score = 2+,3+; iCD8+: intratumoral CD8+; pCD8+:
peritumoral CD8+; iCD163+: intratumoral CD163+; pCD163+: peritumoral CD163+
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shutting down their function in TME ultimately favors
tumor outgrowth. Our original contribution definitively
includes macrophages in this scenario, where conflicting
data have been reported so far [25].
The observation in human tumor biopsies from 10
patients treated with vemurafenib or a combination of dab-
rafenib and trametinib that treatments increased macro-
phages [26, 27], suggests that macrophages are recruited to
the tumor site by BRAFi/MEKi treatment, and that target-
ing macrophages in combination with BRAFi/MEKi may
affect patient response. Tumor-promoting M2 macro-
phages can contribute to tolerance to MAPK inhibition,
and their accumulation within tumors during treatment
strongly correlates with an aggressive phenotype in different
melanoma models, through different mechanisms, includ-
ing VEGF and TNF-alpha secretion. The M2 macrophage
phenotype, promoted by IL-4, IL-13, IL-10 and M-CSF, ap-
pears to contribute to immune suppression through the
production of IL-10 and TGF-β [28]. Present findings are
in line with the protumor function of M2 CD163+ macro-
phages that in combination CD8+ T cells represent predict-
ive prognostic biosignatures in BRAFV600-mutated patients
receiving MAPKi. However, they point on the key predict-
ive role of M2 macrophage level outside and, more import-
antly, inside the tumor at baseline, before the treatment
initiation.
This study presents some strengths: i) patients have been
enrolled and treated homogeneously in IMI centers; ii) the
Fig. 7 Forest plot on progression free survival and overall survival in the validation cohort. Multivariable Cox regression model – Impact of tissue
biomarkers on progression free survival and overall survival.#Adjusted for Stage, treatment (BRAFi+MEKi vs BRAFi); ## Adjusted for Stage, treatment
(BRAFi+MEKi vs BRAFi), subsequent Immunotherapy (yes/no); i: intratumoral; p: peritumoral; CD8+/ CD163+ low: score 0,1+, high: score 2+,3 +
Fig. 6 Kaplan-Meier curves for overall survival according to the combination of intratumoral (a) and peritumoral (b) CD8+ T cells and CD163+
macrophages. Low: score = 0, 1+; High: score = 2+,3+; iCD8+: intratumoral CD8+; pCD8+: peritumoral CD8+; iCD163+: intratumoral CD163+;
pCD163+: peritumoral CD163+
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majority of enrolled and investigated metastatic MPs were
(122/158, 77%) in latest metastatic samples, thus reducing
the potential discordance between primary and metastatic
samples and to better reflect the actual immune biological
status of the patient cohort; iii) semi-automated counting
upon digital image acquisition, which allows unbiased and
rapid quantification of the immune infiltrate in immuno-
stained tissue sections and minimizes significant user errors
due to categorical rankings was adopted; IV) since pro-
spective clinical trials have demonstrated that single-agent
BRAFi and BRAFi+MEKi have different response rates,
PFS, and OS, we addressed this potential bias by accounting
for the difference in treatments in the multivariate model,
V) our findings were validated in an independent patient
cohort, strictly following the Remark checklist [29]. How-
ever, we are aware of the study limitations, including: i) the
retrospective nature of the analysis of prospective collected
cohorts of patients, ii) overall, the time schedule for disease
assessment was similar but not absolutely overlapping in all
patients; iii) complex highly pigmented or necrotic meta-
static melanoma tissues in which macrophages overlap or
fuse together with pigmented melanoma cells forming
densely packed layers of cells were seldom present. Al-
though careful correlation with cell morphology and ac-
curate identification of viable representative tumor areas
were performed, this may represent a confounding factor
that was addressed by optical microscopic evaluation. An-
other point is worthy to be underlined: in our cohort of
metastatic lymph nodes, scoring evaluation did not differ
from the other metastatic sites and positivity for the se-
lected markers was evaluated within the tumor (intratu-
morally) as well as at the interface between the tumor and
immune stroma (peritumorally). Nevertheless, the im-
munologic environment in the lymph node is peculiar and
the crosstalk between specific subsets of lymphocytes and
macrophages in different anatomical lymph node com-
partments may likely yield biological insights not globally
applicable to other metastatic sites.
In our study, the main comparison was between the ex-
treme categories high CD8+/low CD163+ and low CD8+/
high CD163+, and the results of the categories in between
(both low or both high) were instrumental only to confirm
the trend of the risk in the three analyzed groups. The
threshold for statistical significance was set at 0.05, and no
adjustment for multiple tests was planned. The purpose of
our study was to evaluate the impact of a limited number
of biomarkers on prognosis, and these biomarkers should
be prospectively validated in large clinical studies. Never-
theless, the robustness of our results was tested by includ-
ing a validation cohort.
Conclusions
Our findings indicate that a specific preexisting profile
of T and macrophage distribution inside and outside
melanoma dictates the level of resistance to MAPKi.
Our results could have important implications for clin-
ical therapeutic strategies. Since patients with absent/
low intratumoral infiltration of CD8+ cells and high
intratumoral CD163+ cells have a statistically significant
lower ORR and shorter OS, they should deserve a differ-
ent therapeutic strategy. Whether the hostile immune
microenvironment induced by accumulated macro-
phages can be overcome by either inhibiting macrophage
polarization to a M2 phenotype or targeting the inflam-
matory signaling promoted by NF-kB with IkB kinase in-
hibitors is currently unknown. Additional strategies can
include the colony-stimulating factor (CSF)-1R inhibitor
PLX3397 that has been shown to reduce myeloid cell in-
filtration and enhance adoptive cell transfer immuno-
therapy in BRAFV600E-driven melanoma genesis in mice
[30]. Our findings along with other translational studies
support the proposal to design new ad hoc prospective
clinical trials in order to improve long-term survival of
advanced MPs receiving MAPKi. In addition, the present
study further underlines that a better understanding of
the mechanisms that control the recruitment of immune
cells in the TME and their distribution in the intra- and
peritumoral space is essential to devise better thera-
peutic options in metastatic MPs, and particularly in
those undergoing treatment with MAPKi.
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